Clinical Trials Logo
  1. Home
  2. Leukemia, Myeloid
  3. NCT04598789
  4. Details
NCT04598789 Clinical Trial

A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Leukemia, Myeloid Clinical Trial

Official title:
Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04598789
Other study ID # Allo MM HSCT
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 7, 2020
Est. completion date September 1, 2021

Study information
Verified date November 2021
Source Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506

Recruitment information / eligibility
Status Completed
Enrollment 61
Est. completion date September 1, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - children and adults) - HSCT from a one-antigen mismatch unrelated donors - Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017 Exclusion Criteria: none

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• no intervention
no intervention, observational study

Locations
Country Name City State
Italy AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita Turin

Sponsors (1)
Lead Sponsor Collaborator
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary acute GvHD incidence 2012-2017
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT04265963 - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT00233909 - A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT04748848 - A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy Phase 1
Completed NCT04039100 - Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease N/A
Recruiting NCT03600558 - Efficacy of FLAG Regimen for the Treatment of Patients With AML
Completed NCT02538965 - A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT02333838 - Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies Phase 2
Completed NCT01061177 - Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Phase 4
Completed NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Phase 2
Terminated NCT02370888 - Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease Phase 1
Recruiting NCT05805605 - Allo HSCT Using RIC and PTCy for Hematological Diseases Phase 2
Recruiting NCT03080922 - High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML Phase 1/Phase 2
Completed NCT01392989 - Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Phase 2
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Completed NCT00451997 - Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes Phase 2
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Recruiting NCT05458258 - Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
Completed NCT00065143 - Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Phase 2
Recruiting NCT04789655 - Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 1